We previously demonstrated that MC3324 is a dual LSD1 and UTX inhibitor that negatively regulates ERα signaling and promotes activation of programmed cell death pathways in BC both sensitive and resistant to endocrine therapies [21]. This evidence concerns the gene ESR1 and breast cancer.